CVS Health (CVS)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-11-04
$79.96-12.53%
Close 2026-11-04 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-11-04
Research Workspace
Put CVS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Free cash flow at least $9.5 billion in fiscal 2026: Free cash flow: $5.65B.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCVS's integrated model is being dismantled by a planned corporate split. The pharmacy and insurance arms will separate into two companies. Revenue grew 5.4% in the latest quarter. The company beat earnings expectations by 29%. It trades at 9.6 times earnings. The peer median is 24 times earnings. This multiple sits below its own 12 times history. The market expects less growth than our forecast. Free cash flow of $5.65 billion is below the $9.5 billion target. This gap puts the primary pillar under pressure. Peer multiples imply a price about 30% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. CVS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 27 analysts currently covering CVS (as of Nov 2026).
Based on 14 Wall Street analysts offering 12-month price targets for CVS in the last 4 months.
Continue this research
Compare CVS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CVS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
Compare the value case
Put CVS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Separate into two independent, publicly traded companies
Explains strategic rationale for the announced corporate split.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $79.96
The last 12 months of price, then the range of analyst 12-month targets from today’s $79.96.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Separate into two independent, publicly traded companies
Official announcement confirms core strategic objective.
Advances: Separate into two independent, publicly traded companies
Direct execution of core strategic objective to separate entities.
Advances: Increase adjusted EPS guidance
Specific EPS guidance supports growth objective.
Threatens: Maintain revenue guidance of at least $400 billion
Corporate split fundamentally alters revenue structure and guidance basis.
Advances: Increase adjusted EPS guidance
Q3 earnings beat confirms operational resilience despite stock dip.
Reported split threatens current integrated thesis and valuation model.
Pharmacy spin-off report signals major structural change to business model.
